Restricted
Administration
Preparation
Diluent
Treatment of COVID-19 disease in adults and pediatric patients 12 y.o. and older weighing at least 40kg requiring hospitilization
Tier Four
Mechanism of action: inhibitor of SARS-CoV-2 RNA-dependent RNA polymerase
Average half-life: 1 hour
Veklury
Risk of reduced antiviral activity when co-administered with chloroquine or hydroxychloroquine